BIOMARK APPOINTS DR. JEAN-FRANCOIS HAINCE AS STRATEGIC ADVISOR TO GUIDE ITS EXPANSION INTO QUEBEC
![biomark appoints dr jean francois haince as strategic advisor to guide its expansion into quebec](https://www.biomarkdiagnostics.com/wp-content/uploads/2021/05/biomark-appoints-dr-jean-francois-haince-as-strategic-advisor-to-guide-its-expansion-into-quebec.jpg)
Vancouver, British Columbia – (September 16th, 2020) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) is pleased to announce that it has appointed Dr. Jean-Francois (Jeff) Haince as a strategic advisor to its management team. Rashid Ahmed, President and CEO, says, “We are delighted to welcome Dr. Haince into our advisory team. […]
BioMark Receives European Patent for Cancer Diagnostic
![biomark receives european patent for cancer diagnostic](https://www.biomarkdiagnostics.com/wp-content/uploads/2021/05/biomark-receives-european-patent-for-cancer-diagnostic.jpg)
Vancouver, British Columbia – (June 18, 2020) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) announced today that the company has been granted a patent titled “A METHOD FOR ASSAYING THE ACTIVITY OF SPERMIDINE/SPERMINE N1-ACETYLTRANSFERASE.” The method comprises correlating a presence of the acetylated metabolite of rimantadine or tocainide to spermidine/spermine N1-acetyltransferase […]